Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss drug maker says it has agreed with FDA on a Phase III trial design for the combination respiratory drug QVA149 and expects to file in late 2014; plan now calls for testing a twice-daily dose in addition to once-daily.
You may also be interested in...
GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose
The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.
GSK And Novartis Look To Emerging Markets Even As Growth Slowed In Q1 – Emerging Market Earnings Roundup (Part 3)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya
A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.